Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trialRafael Rosell, Rolf A. Stahel, Urania Dafni et al.|The Lancet Respiratory Medicine|2017Cited by 184
Treatment of the Elderly When Cure is the Goal: The Influence of Age on Treatment Selection and Efficacy for Stage III Non-small Cell Lung CancerLinda Coate, Frances A. Shepherd, Shaf Keshavjee et al.|Journal of Thoracic Oncology|2011Cited by 56
Neoadjuvant chemoradiation and surgery improves survival outcomes compared with definitive chemoradiation in the treatment of stage IIIA N2 non-small-cell lung cancerGail Darling, Fei Li, Demetris Patsios et al.|European Journal of Cardio-Thoracic Surgery|2015Cited by 44
Illness intrusiveness and subjective well-being in patients with glioblastomaKim Edelstein, Gerald M. Devins, Linda Coate et al.|Journal of Neuro-Oncology|2015Cited by 39
Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non–Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung TrialSolange Peters, Egbert F. Smit, Rolf A. Stahel et al.|Journal of Thoracic Oncology|2016Cited by 22